Glasser SP, Vitolins M, Rocco MV, et al. - Findings of the SPRINT trial revealed that medication adherence (as measured using the 8-item Morisky Medication Adherence Scale) was neither associated with outcomes nor with BP control.

• A total of 9,361 participants (aged ≥ 50) in the SPRINT Trial were analyzed to determine if adherence and cardiovascular outcomes are associated irrespective of intervention.

• Participants were randomly assigned to a Standard Treatment Group (targeted SBP <140 mmHg) or an Intensive Treatment Group (targeted SBP <120 mmHg).

• The MMAS-8 was employed.

• A higher BMI, SBP, DBP, and PHQ-9 was noted in relation to low adherence, and a higher MOCA was observed in relation to high adherence.

• Baseline odds ratios for primary outcome (a composite of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes) were 1.02, 1.07, and 1.05 for the low vs medium and vs high; and, for medium vs high MMAS-8.